Anti-TNF treatment in ankylosing spondylitis patients with chronic kidney disease: Is it effective and safe?

---

Copy For Citation

Coşkun B. N., Yagiz B., Corabay S. G., Pehlivan Y., Dalkılıç H. E.

EUROPEAN JOURNAL OF RHEUMATOLOGY, vol.9, no.2, pp.68-74, 2022 (ESCI)

• Publication Type: Article / Article
• Volume: 9 Issue: 2
• Publication Date: 2022
• Doi Number: 10.5152/eurjrheum.2022.21099
• Journal Name: EUROPEAN JOURNAL OF RHEUMATOLOGY
• Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
• Page Numbers: pp.68-74
• Keywords: Ankylosing spondylitis, anti-TNF drugs, chronic kidney disease, efficacy, safe, STAGE RENAL-DISEASE, SECONDARY AMYLOIDOSIS, RHEUMATOID-ARTHRITIS, RISK, ETANERCEPT, PREVALENCE, SPONDYLOARTHRITIS, METHOTREXATE, ADALIMUMAB, INFECTIONS
• Bursa Uludag University Affiliated: Yes

Abstract

Objective: This study aims to examine the efficacy and safety of the antitumor necrosis factor (TNF) drugs in ankylosing spondylitis (AS) patients with chronic kidney disease.